Actelion Pharmaceuticals US, Inc. drugs

6 results

  • opsumit

    (macitentan)
    Actelion Pharmaceuticals US, Inc.
    OPSUMIT is indicated for treating pulmonary arterial hypertension (PAH, WHO Group I) to reduce disease progression and hospitalization risks. Its effectiveness was demonstrated in a long-term study involving patients with various forms of PAH, primarily those with WHO Functional Class II–III symptoms.
    Medication Details
    Drug Interactions

  • tracleer

    (bosentan)
    Actelion Pharmaceuticals US, Inc.
    TRACLEER is indicated for treating pulmonary arterial hypertension (PAH) in adults and pediatric patients (3 years and older) to improve exercise ability and reduce clinical worsening. It is effective for idiopathic, heritable, and PAH associated with connective tissue or congenital heart diseases.
    Medication Details
    Drug Interactions

  • veletri

    (epoprostenol)
    Actelion Pharmaceuticals US, Inc.
    VELETRI is indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to enhance exercise capacity, primarily in patients with NYHA Functional Class III–IV symptoms, including idiopathic or heritable PAH and PAH linked to connective tissue diseases.
    Medication Details
    Drug Interactions

  • zavesca

    (miglustat)
    Actelion Pharmaceuticals US, Inc.
    ZAVESCA is indicated as monotherapy for treating adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not suitable, such as in cases of allergy, hypersensitivity, or poor venous access.
    Medication Details